Dr. Roué on ​the Next Steps ​With TG-1701 in MCL

Video

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses the next steps with the investigational BTK inhibitor TG-1701 in mantle cell lymphoma.

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses the next steps with the investigational BTK inhibitor TG-1701 in mantle cell lymphoma (MCL). 

Investigators are working to characterize the production of inflammatory cytokines with TG-1701, says Roué.

Research efforts are also trying to understand the activity of TG-1701 and why this activity is lost during activation of the nuclear factor kappa-light-chain-enhancer of activated B cells, explains Roué. In the event of overexpressed signaling, the activity of this molecule is broad. 

More information and improved technical analyses are needed to observe the inhibitor and its role in BTK inhibition, Roué concludes.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS